Andreas Burchert
Andreas Burchert is an expert in Hematology at Universitätsklinikum Gießen und Marburg (Germany). As of October 2026, ScienceLeadR ranks Andreas Burchert in the top 1% of experts worldwide for Leukemia. Andreas Burchert has authored 238 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 2 of them ongoing. SLR score: 1,010 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Transplantation - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2002 - 2026
Number : 238
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl-2 and Mcl-1 blockade in preclinical glioblastoma models. PMID 42920362 — cells, genes, bcl-2, sirolimus, azacitidine, glioblastoma, therapeutics, apoptosis | FEBS Open Bio | 2026 | 0 |
| Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia. PMID 42758645 — hematology, classification, leukemia, drug therapy, leukemia, myeloid, acute, leukemia, myeloid, protein-tyrosine kinases, tyrosine, chemotherapy | Blood | 2026 | 0 |
| Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification. PMID 42622110 — hematology, cytarabine, leukemia, leukemia, myeloid, acute, leukemia, myeloid, mitoxantrone, transplants, therapeutics | Haematologica | 2026 | 0 |
| Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study. PMID 42610785 — cells, fms-like tyrosine kinase 3, microscopy, electron, scanning transmission, stem cells, maintenance, protein-tyrosine kinases, transplants, tyrosine, therapeutics, cell transplantation, stem cell transplantation, vascular endothelial growth factor receptor-1, mutation, transplantation | Br J Haematol | 2026 | 0 |
| Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. PMID 42315627 — cells, genes, communication, adaptive immunity, leukemia, biomarkers, leukemia, myeloid, immunity, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive | Leukemia | 2026 | 3 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase I II First In Human Clinical Trial to Evaluate the Safety Tolerability and Anti Tumor Activity of IMA402 a Bispecific T Cell Engaging Receptor Molecule (TCER ) targeting PRAME as Monotherapy or in Combination with a Checkpoint Inhibitor in Patients with Recurrent and or Refractory Solid Tumors 2022-503133-54-00 — cells, safety, neoplasms, t-lymphocytes | Phase 1/Phase 2 | Recruiting | 2023 |
| A multicentre randomized trial in adults with de novo Philadelphia Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low intensity chemotherapy to compare end of therapy with indication for SCT versus TKI blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab in suboptimal responders (GMALL EVOLVE) 2024-517966-40-00 — precursor cell lymphoblastic leukemia-lymphoma, leukemia, drug therapy, therapeutics, chromosomes, philadelphia chromosome, chemotherapy | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map